|1.||Panda, Dulal: 3 articles (05/2015 - 06/2004)|
|2.||Heneberg, Petr: 1 article (09/2015)|
|3.||Pech, Pavel: 1 article (09/2015)|
|4.||Mondello, Chiara: 1 article (06/2015)|
|5.||Desaulniers, Daniel: 1 article (06/2015)|
|6.||Van Schooten, Frederik J: 1 article (06/2015)|
|7.||Olsen, Ann-Karin: 1 article (06/2015)|
|8.||Charles, Amelia K: 1 article (06/2015)|
|9.||Al-Temaimi, Rabeah: 1 article (06/2015)|
|10.||Singh, Neetu: 1 article (06/2015)|
06/01/1993 - "In general, the effects were small, but it was observed that benomyl and MBC significantly induced micronuclei as well as aneugenic effects, hyperdiploidy (no metaphases with more than one or two extra chromosomes, 2n + 1 or 2n + 2, were observed) and polyploidy (4n). "
10/01/1984 - "Morphological and genetic effects of benomyl on polyploid brewing yeasts: isolation of auxotrophic mutants."
12/01/1990 - "We found a dose-dependent increase in frequency of aneuploidy, but a much more marked induction of polyploidy was noted at the highest benomyl concentration. "
12/01/1990 - "Use of a cell hybrid test system to demonstrate that benomyl induces aneuploidy and polyploidy."
05/01/1994 - "Strain SAS56, an ascospore line used routinely for genetic analyses, is probably polyploid, since treatment with benomyl causes a significant reduction in DNA content per nucleus. "
09/01/2002 - "The deficiencies in defining the MOA for benomyl/MBC introduce uncertainties into the analysis; consequently, benomyl/MBC induction of aneuploidy cannot be definitively linked to mouse liver carcinogenicity at this time."
07/01/1992 - "Benomyl-induced aneuploidy in mouse oocytes."
01/01/1990 - "In human lymphocytes, benomyl at concentrations of 0.5, 1.0, and 2.0 micrograms/ml decreased the number of cells undergoing third division whereas at the concentrations of 0.25 to 4.0 micrograms/ml it strongly increased the number of aneuploid cells. "
08/01/1983 - "Induction of mitotic crossing over and aneuploidy by benomyl was rather slight (up to 0.05 and 0.006%, respectively)."
03/01/1981 - "Analysis of the segregants of the diploids or aneuploids, induced by Benomyl, indicated that multiple genes were responsible for cold sensitivity in each Cs-37 mutant, since segregants with various levels of cold sensitivity were obtained. "
09/01/2010 - "Cells deleted of SUM1 showed hypersensitivity to benomyl and cold-sensitive growth, phenotypes exhibited by mutants defective in microtubule function and cytoskeletal defects. "
06/01/2006 - "They also rendered hypersensitivity to low doses of the microtubule-depolymerizing agent benomyl for conidiation. "
05/01/1998 - "Mutations in sldA and sldB also confer hypersensitivity to the microtubule-destabilizing drug benomyl. "
12/01/1997 - "Deletion of BIM1 results in a strong bilateral karyogamy defect, hypersensitivity to benomyl, and aberrant spindle behavior, all phenotypes associated with mutations affecting microtubules in yeast, and inviability at extreme temperatures (i.e., >/=37 degrees C or </=14 degrees C). "
03/15/1995 - "Analysis of the arrest morphology and of the survival during arrest strongly suggests a structural defect accounting for the benomyl hypersensitivity, rather than a regulatory defect in a checkpoint. "
|4.||Body Weight (Weight, Body)
11/01/1991 - "Adult male Sprague-Dawley rats (100 days of age) were given single oral doses of the fungicide benomyl (methyl 1-(butylcarbamoyl)-2- benzimidazolecarbamate) in dosages ranging from 25 to 800 mg/kg body weight. "
02/01/1989 - "In addition, male rats exposed to 200 mg/m3 benomyl had depressed mean body weights compared to controls and this finding correlated with a reduction in food consumption. "
01/01/1986 - "Lungs were a smaller portion of body weight in fetuses of benomyl-treated dams in both diet groups. "
07/01/1991 - "Benomyl, a benzimidazole fungicide, produced ocular and craniocerebral malformations in fetal rats when administered to the dams by gavage in a dose of 62.4 mg/kg of maternal body weight/day on days 7-21 of gestation. "
01/01/1987 - "Benomyl, a benzimidazole fungicide, produced craniocerebral and systemic malformations in fetal rats when administered by gavage in doses of 31.2, 62.5, and 125 mg/kg of maternal body weight on days 7-21 of gestation. "
05/01/2015 - "Mechanism of Anti-Cancer Activity of Benomyl Loaded Nanoparticles in Multidrug Resistant Cancer Cells."
09/01/2006 - "Considering the very high toxicity of the potent anticancer drugs and the low toxicity of benomyl in humans, we suggest that benomyl could be useful as an adjuvant in combination with the powerful anticancer drugs in cancer therapy."
09/01/2006 - "Suppression of microtubule dynamics by benomyl decreases tension across kinetochore pairs and induces apoptosis in cancer cells."
09/01/2002 - "The data show that by 14 days of benomyl treatment, events associated with liver toxicity appear to set in motion the sequence of actions that leads to neoplasms. "
06/01/2004 - "The greater than expected actions of benomyl on mammalian microtubules and mitosis together with its relatively low toxicity suggest that it might be useful as an adjuvant in cancer chemotherapy."
|1.||DNA (Deoxyribonucleic Acid)
|2.||Griseofulvin (Grifulvin V)
|3.||Mercaptoethanol (2 Mercaptoethanol)
|10.||2,4-Dichlorophenoxyacetic Acid (2,4 Dichlorophenoxyacetic Acid)
|1.||Drug Therapy (Chemotherapy)